Trial RPCEC00000359
Publication Hernandez-Bernal F, SSRN, 2022
Primary outcome on the report: The efficacy of Abdala vaccine in preventing a first occurrence of symptomatic COVID-19, in individuals without evidence of prior exposure to SAR-CoV-2 infection with onset 14 days after the third dose of the immunization schedule

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.